Mehtamphetamin Abuse Disorder. Other stimulant abuse with stimulant-induced psychotic disorder
Conditions
Interventions
Methamphetamine users treated with atomoxetine, including 56 people who referred to the addiction clinic of Amirkabir Hospital with a history of methamphetamine use who intend to be treated. If these
The second group 56 Methamphetamin abuser treated with NAC, this medicine starts with a dose of 600 mg per day in the form of a 600 mg NAC effervescent tablet made by Hakim Pharmaceutical Company, o
Sponsors
Arak University of Medical Sciences
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Age between 18 and 50 years; Suffering from amphetamine abuse based on the diagnosis of a psychiatric specialist; No history of allergy to Atomoxetine or NAC Absence of contraindications for atomoxetine or NAC (contraindications for NAC include a history of allergy and asthma, and contraindications for atomoxetine include a history of allergy, angle-closure glaucoma, advanced cardiovascular problems, pheochromocytoma, and use ofMAo-inhibiting drugs in the last two weeks ) Informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Prescribing medications that interact with atomoxetine such as MAO inh Pregnancy and Breastfeeding Suffering from malignant hypertension (higher than 110/180)- Suffering from chronic kidney and liver disease Suffering from serious neurological and mental disorders based on a DSM, including schizophrenia and schizoaffective disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Craving to Methamphetamine. Timepoint: Assessment of craving for Methamphetamine in 0, 2, 4, 6, 8 weeks from beginning of trial. Method of measurement: Questionnaire to measure the temptation to use drugs after quitting (Federdi, Barerfan and Ziyai; 2008). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarideh Ranjbaran
Arak University of Medical Sciences
Outcome results
None listed